302 related articles for article (PubMed ID: 16682511)
1. Assessment of serum free light chain assays for plasma cell disorder screening in a Veterans Affairs population.
Abadie JM; Bankson DD
Ann Clin Lab Sci; 2006; 36(2):157-62. PubMed ID: 16682511
[TBL] [Abstract][Full Text] [Related]
2. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the analytical performance and the sensitivity of serum free light chains immunoassay in patients with monoclonal gammopathy.
Wolff F; Thiry C; Willems D
Clin Biochem; 2007 Mar; 40(5-6):351-4. PubMed ID: 17239359
[TBL] [Abstract][Full Text] [Related]
4. [Assessment of serum free light chain of patients with multiple myeloma and clinical significance thereof].
Sui WW; Yao HJ; Wang YF; Wang L; Zhang K; Xu Y; Qiu LG
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3158-60. PubMed ID: 18269880
[TBL] [Abstract][Full Text] [Related]
5. Clinical and preclinical validation of the serum free light chain assay: identification of the critical difference for optimized clinical use.
Hansen CT; Münster AM; Nielsen L; Pedersen P; Abildgaard N
Eur J Haematol; 2012 Dec; 89(6):458-68. PubMed ID: 22998393
[TBL] [Abstract][Full Text] [Related]
6. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis.
Akar H; Seldin DC; Magnani B; O'Hara C; Berk JL; Schoonmaker C; Cabral H; Dember LM; Sanchorawala V; Connors LH; Falk RH; Skinner M
Amyloid; 2005 Dec; 12(4):210-5. PubMed ID: 16399645
[TBL] [Abstract][Full Text] [Related]
7. Serum free light chain analysis.
Davids MS; Murali MR; Kuter DJ
Am J Hematol; 2010 Oct; 85(10):787-90. PubMed ID: 20721885
[TBL] [Abstract][Full Text] [Related]
8. Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis.
Jaskowski TD; Litwin CM; Hill HR
Clin Vaccine Immunol; 2006 Feb; 13(2):277-80. PubMed ID: 16467338
[TBL] [Abstract][Full Text] [Related]
9. Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine.
Campbell JP; Cobbold M; Wang Y; Goodall M; Bonney SL; Chamba A; Birtwistle J; Plant T; Afzal Z; Jefferis R; Drayson MT
J Immunol Methods; 2013 May; 391(1-2):1-13. PubMed ID: 23388695
[TBL] [Abstract][Full Text] [Related]
10. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
[TBL] [Abstract][Full Text] [Related]
11. Quantification of serum free light chain kappa and lambda by the SPAPLUS analyser.
Maisin D; Lepoutre T; Gruson D; Wallemacq P
Clin Biochem; 2013 May; 46(7-8):622-6. PubMed ID: 23291296
[TBL] [Abstract][Full Text] [Related]
12. Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies?
Beetham R; Wassell J; Wallage MJ; Whiteway AJ; James JA
Ann Clin Biochem; 2007 Nov; 44(Pt 6):516-22. PubMed ID: 17961305
[TBL] [Abstract][Full Text] [Related]
13. Serum free light chains for monitoring multiple myeloma.
Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
[TBL] [Abstract][Full Text] [Related]
14. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
Dispenzieri A; Kyle R; Merlini G; Miguel JS; Ludwig H; Hajek R; Palumbo A; Jagannath S; Blade J; Lonial S; Dimopoulos M; Comenzo R; Einsele H; Barlogie B; Anderson K; Gertz M; Harousseau JL; Attal M; Tosi P; Sonneveld P; Boccadoro M; Morgan G; Richardson P; Sezer O; Mateos MV; Cavo M; Joshua D; Turesson I; Chen W; Shimizu K; Powles R; Rajkumar SV; Durie BG;
Leukemia; 2009 Feb; 23(2):215-24. PubMed ID: 19020545
[TBL] [Abstract][Full Text] [Related]
15. Serum free light chain reference values: a critical approach.
Altinier S; Seguso M; Zaninotto M; Varagnolo M; Adami F; Angeli P; Plebani M
Clin Biochem; 2013 May; 46(7-8):691-3. PubMed ID: 23384536
[TBL] [Abstract][Full Text] [Related]
16. Polyclonal free light chain of Ig may interfere with interpretation of monoclonal free light chain κ/λ ratio.
Levinson SS
Ann Clin Lab Sci; 2010; 40(4):348-53. PubMed ID: 20947809
[TBL] [Abstract][Full Text] [Related]
17. Are renal reference intervals required when screening for plasma cell disorders with serum free light chains and serum protein electrophoresis?
Abadie JM; van Hoeven KH; Wells JM
Am J Clin Pathol; 2009 Feb; 131(2):166-71. PubMed ID: 19141376
[TBL] [Abstract][Full Text] [Related]
18. Use of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant plasma cell disorders.
Vermeersch P; Vercammen M; Holvoet A; Vande Broek I; Delforge M; Bossuyt X
Clin Chim Acta; 2009 Dec; 410(1-2):54-8. PubMed ID: 19778527
[TBL] [Abstract][Full Text] [Related]
19. Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis.
Hoedemakers RM; Pruijt JF; Hol S; Teunissen E; Martens H; Stam P; Melsert R; Te Velthuis H
Clin Chem Lab Med; 2011 Nov; 50(3):489-95. PubMed ID: 22098433
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder.
Vermeersch P; Van Hoovels L; Delforge M; Mariën G; Bossuyt X
Br J Haematol; 2008 Nov; 143(4):496-502. PubMed ID: 18729849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
